Open Source Securities released a research report on April 16 stating that it maintains the buying rating of 600535.SH (). The main reasons for the rating include: 1) steady revenue growth, reversing losses in net profit due to mother; 2) steady revenue growth in cardiovascular, cold and fever fields, and liver disease treatment products are disrupted by collection factors; 3) R&D and innovation continue to advance, and traditional Chinese medicine, biopharmaceuticals, and chemicals are developing collaboratively. (Mainichi Keizai Shimbun)
开源证券4月16日发布研报称，维持天士力（600535.SH）买入评级。评级理由主要包括：1）营收稳健增长，归母净利润扭亏；2）心脑血管、感冒发烧等领域营收增长稳健，肝病治疗产品受集采因素扰动；3）研发创新持续推进，中药、生物药、化药协同发展。（每日经济新闻）
Open Source Securities released a research report on April 16 stating that it maintains the buying rating of 600535.SH (). The main reasons for the rating include: 1) steady revenue growth, reversing losses in net profit due to mother; 2) steady revenue g
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.